The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

The invention provides therapeutic compositions containing willow extract, such as willow leaf extract, methods of medical treatment using such compositions, and methods for preparing such compositions.

The invention provides therapeutic compositions containing willow extract, such as willow leaf extract, methods of medical treatment using such compositions, and methods for preparing such compositions.

The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered. Measuring gut permeability may include enterally administering a second dosage of the composition, measuring a second amount of the administered dose, and determining a second total percentage of the administered dose recovered.

The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered. Measuring gut permeability may include enterally administering a second dosage of the composition, measuring a second amount of the administered dose, and determining a second total percentage of the administered dose recovered.

The technology described herein is directed to polypeptide systems using drug-controlled peptide docking domains and cognate docking domain-binding peptides and their use to control cellular signaling, activity, and/or gene expression.

The technology described herein is directed to polypeptide systems using drug-controlled peptide docking domains and cognate docking domain-binding peptides and their use to control cellular signaling, activity, and/or gene expression.

This invention relates to a novel anti-RNA, including anti-SARS-CoV-2, viral pharmaceutical composition of Avipiravir in tablets or capsules containing 40-48 wt % of micronized favipiravir, the other ingredients being excipients.

The drug Antiprovir for the prevention and treatment of coronavirus disease COVID-19 is a pharmaceutical composition in the form of coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (44.1% by weight-45.6% by weight) with a particle size of 40-211 microns, the other ingredients being excipients.

This invention relates to a novel anti-RNA, including anti-SARS-CoV-2, viral pharmaceutical composition of Avipiravir in tablets or capsules containing 40-48 wt % of micronized favipiravir, the other ingredients being excipients.

The drug Antiprovir for the prevention and treatment of coronavirus disease COVID-19 is a pharmaceutical composition in the form of coated tablets containing 200 mg, 300 mg, 400 mg, or 600 mg of micronized favipiravir (44.1% by weight-45.6% by weight) with a particle size of 40-211 microns, the other ingredients being excipients.

This invention relates to a novel method for treating RNA viral infections including COVID-19 (SARS-CoV-2).

A method for treating RNA viral infections, including COVID-19 (SARS-CoV-2), which consists in administering to the patient a pharmaceutical composition in the form of a tablet, capsule, pill, or powder containing Favipiravir as the active ingredient at a dose of ≥40 mg/kg/day on day 1 and at a dose of ≥16 mg/kg/day on subsequent days until the virus leaves the body, optionally in combination with concomitant medications.